The management of malignant pleural mesothelioma; single centre experience in 10 years.
about
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational healthIdentification of novel autoantibodies for detection of malignant mesotheliomaCurrent issues in malignant pleural mesothelioma evaluation and managementGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaSurgical treatment of malignant pleural mesothelioma.BTS statement on malignant mesothelioma in the UK, 2007.Management of malignant mesothelioma by decortication and adjunct phototherapy.Overview of treatment related complications in malignant pleural mesothelioma.Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.What is the role of radiotherapy in malignant pleural mesothelioma?Unusual presentation and location pleural malignant mesothelioma.Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational studyCurrent concepts in malignant pleural mesothelioma.Biomarkers for malignant pleural mesothelioma: current status.Surgery for malignant pleural mesothelioma.Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.Diagnostic molecular biomarkers for malignant pleural effusions.Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.Management of malignant pleural mesothelioma-The European experience.Current surgical strategies for malignant pleural mesothelioma.Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesotheliomaInduction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma.Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.Blood Loss and Massive Transfusion in Patients Undergoing Major Oncological Surgery: What Do We Know?
P2860
Q26821919-13A26178-4809-4F31-9652-DF448CECB63CQ28387447-E20B8AE8-8989-40CC-B303-0E832FD539FDQ28393560-EA7F3EDB-CF7C-46B2-B562-589F6FC6EBD9Q28394028-14150F53-0753-4ABE-9F8B-CBE57E9C63DFQ30401535-0421096F-4491-491D-BAF9-18CCBE2B48F3Q30478994-66D88B53-E73D-4221-99F8-FD8FD453EB8BQ33244201-F63FD0E4-3ED6-4F07-A434-9F3EFD5405CAQ33871599-7430DDE3-BF4F-46E2-9E60-46960DFFCBD7Q35141809-065CF2DB-5687-4E44-AD92-C9FAB1EE2B3DQ35584463-C9582327-23FB-4831-9E79-AC14AC858486Q36986796-A6842B36-9CC1-43BD-945E-BAB49DA81739Q37052430-F72D4DC8-9757-4801-9069-1A3DCC9A6C8FQ37086026-8B4F3AB0-5C45-4C10-BEC8-61B278C4F310Q37335377-D0900154-A7E3-409B-883D-B8E5C793C23FQ37762833-4678BACC-1369-407C-8417-F9D2EED974ACQ37867989-D0B59C71-4F96-40FF-9348-1EAFB0FF4992Q37889963-242FFF7C-FF87-4D59-BED9-0910CA4DFBF8Q38195607-6A9AB131-205E-4B83-B852-F4DBF4D3E636Q38215513-539EEBD3-5841-403A-B565-6EFF5932E3D9Q38641574-C383E5ED-FC03-46F4-B3E3-AD0237B8FDDDQ39290976-07659636-3CD9-410F-9B2B-6AF9D45FD19BQ40210704-70214D3B-E3B7-4C9B-B353-FDDABCBB1B2BQ46122543-AF20573D-500D-4722-9776-039D8DE628ABQ46858872-FC9182F9-F792-4BF7-A336-D868B809BCFEQ49708022-718EEB7B-96A5-4987-A971-509AEBFAE351Q51760705-6AD28300-D230-4087-B764-B636EAFEDA7AQ53586030-5B0E258F-1D04-4510-B791-9E43183BE6D0Q58693283-E15E9B15-2C61-422E-9196-C1CD86E7F9C8
P2860
The management of malignant pleural mesothelioma; single centre experience in 10 years.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@ast
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@en
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@nl
type
label
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@ast
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@en
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@nl
prefLabel
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@ast
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@en
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@nl
P2093
P1476
The management of malignant pleural mesothelioma; single centre experience in 10 years.
@en
P2093
Ali Jilaihawi
Dhruva Prakash
Tarek Aziz
P304
P356
10.1016/S1010-7940(02)00273-7
P577
2002-08-01T00:00:00Z